EQS-News: Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform

EQS-News: Heidelberg Pharma AG / Key word(s): Alliance Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University o...

December 17, 2022
11:04 AM

EQS-News: Heidelberg Pharma AG / Key word(s): Alliance Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform 16.12.2022 / 09:55 CET/CEST The issuer is solely responsible for the content of this announcement.PRESS RELEASE Heidelberg Pharma Signs Research and Exclusive Option Agreement with Binghamton University on Immunostimulatory Technology Platform Ladenburg, Germany, 16 December 2022 Heidelberg Pharma AG (FSE: HPHA) today announced that it has entered into a research and exclusive option agreement with Binghamton University, State University of New York, Binghamton, NY, USA, related to a novel and proprietary immunostimulatory technology platform.